Xenon Pharmaceuticals (XENE) Gains from Investment Securities (2016 - 2025)
Historic Gains from Investment Securities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $11.2 million.
- Xenon Pharmaceuticals' Gains from Investment Securities rose 155.19% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 155.19%. This contributed to the annual value of $10.7 million for FY2024, which is 2040.35% up from last year.
- Per Xenon Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $11.2 million for Q3 2025, which was up 155.19% from $11.7 million recorded in Q2 2025.
- In the past 5 years, Xenon Pharmaceuticals' Gains from Investment Securities registered a high of $30.4 million during Q4 2024, and its lowest value of -$518000.0 during Q1 2025.
- Moreover, its 5-year median value for Gains from Investment Securities was $8.0 million (2022), whereas its average is $9.0 million.
- In the last 5 years, Xenon Pharmaceuticals' Gains from Investment Securities soared by 24196.41% in 2024 and then skyrocketed by 155.19% in 2025.
- Quarter analysis of 5 years shows Xenon Pharmaceuticals' Gains from Investment Securities stood at $5.6 million in 2021, then increased by 26.24% to $7.1 million in 2022, then increased by 24.96% to $8.9 million in 2023, then skyrocketed by 241.96% to $30.4 million in 2024, then crashed by 63.23% to $11.2 million in 2025.
- Its last three reported values are $11.2 million in Q3 2025, $11.7 million for Q2 2025, and -$518000.0 during Q1 2025.